LAMC Therapy

What is Poly-MVA? Aka LAMC (lipoic acid mineral complex)

Is a complex is a proprietary blend on trace minerals and palladium irreversibly bound to two molecules of the antioxidant lipoic acid. Alpha lipoic acid is a powerful antioxidant which our body makes at small levels in our cells’ mitochondria. Antioxidants neutralize free radical damage that causes damage and the conditions associated with aging. Due to the specific nature of lipoic acid, poly-MVA treatments are associated with conditions of mitochondrial dysfunction:

Cachexia associated with cancer therapies

Cardiac disease (stroke, post-heart attack, disease with compromised oxygen flow)

Diabetes

Endometriosis

Chronic fatigue syndrome (HIV-associated fatigue)

Lyme Disease

Neurological Condition: Alzheimer’s Disease, Cognitive decline, Dementia, Parkinson’s Disease, Multiple Sclerosis, fibromyalgia, neuropathy,

What to expect from treatment?

Poly-MVA /LAMC has little to no side effects for the majority of individuals. However, the therapy is very stimulating to the mitochondria and detoxification pathways. Some rare side effects include fatigue, headache, and rash. To avoid any complications, testing doses and titration is recommended. It can take 2-4 infusions to get to a therapeutic dose. Most patients report increased energy levels after 2-4 weeks of bi-weekly infusions at a therapeutic dose. Depending on treatment goals, a standard therapeutic trial consists of 4-6 weeks of infusions twice a week. 

Ingredients in IV Poly MVA

⍺-lipoic acid

Palladium  

B vitamins: B1 (thiamin), B2 (riboflavin), B12 cobalamin

Amino acids: N-acetyl cysteine, formyl methionine

Trace amounts: rhodium, ruthenium, molybdenum

References

1.    Antonawich FJ, Fiore SM, Welicky LM. Regulation of ischemic cell death by the lipoic acid-palladium complex, Poly MVA, in gerbils. Exp Neurol. 2004 Sep;189(1):10-5. doi: 10.1016/j.expneurol.2004.05.011. PMID: 15296831.

2.    Bacon AL, Harris AL. Hypoxia-inducible factors and hypoxic cell death in tumour physiology. Ann Med. 2004;36(7):530-9. doi: 10.1080/07853890410018231. PMID: 15513303.

3.    Brown JM, Wilson WR. Exploiting tumour hypoxia in cancer treatment. Nat Rev Cancer. 2004 Jun;4(6):437-47. doi: 10.1038/nrc1367. PMID: 15170446.

4.    Bünger J, Stork J, Stalder K. Cyto- and genotoxic effects of coordination complexes of platinum, palladium and rhodium in vitro. Int Arch Occup Environ Health. 1996;69(1):33-8. doi: 10.1007/BF02630736. PMID: 9017432.

5.    Gebel T, Lantzsch H, Plessow K, Dunkelberg H. Genotoxicity of platinum and palladium compounds in human and bacterial cells. Mutat Res. 1997 Mar 17;389(2-3):183-90. doi: 10.1016/s1383-5718(96)00145-3. PMID: 9093382.

6.    Sudheesh NP, Ajith TA, Janardhanan KK, Krishnan CV. Palladium alpha-lipoic acid complex formulation enhances activities of Krebs cycle dehydrogenases and respiratory complexes I-IV in the heart of aged rats. Food Chem Toxicol. 2009 Aug;47(8):2124-8. doi: 10.1016/j.fct.2009.05.032. Epub 2009 Jun 13. PMID: 19500641.